Schizophrenia Clinical Trials in Oklahoma City, Oklahoma

4 studies are recruiting for schizophrenia in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Local Institution - 0047, Oklahoma City, Oklahoma

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Sooner Clinical Research, Oklahoma City, Oklahoma

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

3. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

   The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

   Stage

   Not phased

   Ages

   18 and older

   Site

   The Rivus Wellness & Research Institute, Oklahoma City, Oklahoma

   Locations

   55 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07379827 on ClinicalTrials.gov

4. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

   This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Reviva site, Oklahoma City, Oklahoma

   Locations

   18 in total

   Run by

   Reviva Pharmaceuticals

   See if you can join NCT05184335 on ClinicalTrials.gov